SK Biopharmaceuticals
SK Biopharmaceuticals, a leading player in the pharmaceutical preparation manufacturing industry, is headquartered in South Korea (KR). Founded in 2011, the company has rapidly established itself as a key innovator in the development of novel therapeutics, particularly in the fields of neurology and oncology.
With a strong focus on research and development, SK Biopharmaceuticals offers a range of unique products, including innovative treatments that address unmet medical needs. The company has achieved significant milestones, including successful global partnerships and the launch of groundbreaking therapies that enhance patient outcomes.
Recognised for its commitment to quality and innovation, SK Biopharmaceuticals continues to strengthen its market position, contributing to advancements in healthcare both domestically and internationally.
+1 vs industry average
SK Biopharmaceuticals’s score of 39 is higher than 53% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Part of the Sustainability team at SK Biopharmaceuticals?
- Control how your company's emission story is told
- Respond to customers efficiently
- See who's viewing your profile
Industry Intensity
Pharmaceutical Preparation Manufacturing has below-average carbon intensity
Industry performance
The Pharmaceutical Preparation Manufacturing industry has increased its overall emissions by 132% since 0
Emissions trajectory 2020 – 2026
Reported emissions
Scope 3 accounts for ••• of total emissions.
SK Biopharmaceuticals's reported carbon emissions
SK Biopharmaceuticals, headquartered in South Korea and operating within the Pharmaceutical Preparation Manufacturing industry, reported a total of approximately 14.3 million kg CO2e in emissions for the year 2023. This figure encompasses Scope 1, Scope 2, and Scope 3 emissions.
For the year 2022, the company's total emissions were approximately 8.4 million kg CO2e. In 2021, SK Biopharmaceuticals's Scope 1 and Scope 2 emissions totalled approximately 1.3 million kg CO2e, with Scope 3 data not disclosed for that year. The company's emissions for 2020 were approximately 1.2 million kg CO2e (Scope 1 and 2), and for 2019, approximately 1.1 million kg CO2e (Scope 1 and 2). In 2018, emissions (Scope 1 and 2) were approximately 1.2 million kg CO2e.
While SK Biopharmaceuticals has disclosed its emissions data, specific reduction targets and commitments are not detailed in the provided information. The company's climate data is sourced from SK Biopharmaceuticals Co., Ltd. It's noted that some data points, such as Scope 3/purchased goods and services, are marked as missing.
Unlock detailed emission data
Access structured emission data, company specific factors and auditable source documents
SK Biopharmaceuticals’s Climate Goals (2030 & 2050)
No climate goals have been disclosed for SK Biopharmaceuticals yet.
Scope 3 top emissions categories
No scope 3 category breakdown has been disclosed yet.
Climate initiatives

Science Based Targets Initiative
Inherited from SK Inc.
Carbon Disclosure Project
The Climate Pledge
UN Global Compact Climate Champions initiative
RE 100
Climate Action 100
Emissions comparison with industry peers
View similar organisationsUsage policy
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Where does DitchCarbondata come from?
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn moreCurious to see your top suppliers emissions?
Book a demo for a pilot project